riluzole has been researched along with Akinetic-Rigid Variant of Huntington Disease in 24 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the dosage-related impact of riluzole on chorea in HD." | 5.10 | Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. ( , 2003) |
| "If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit." | 3.78 | Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. ( Armstrong, MJ; Miyasaki, JM, 2012) |
| "Riluzole was well tolerated." | 2.70 | Riluzole in Huntington's disease (HD): an open label study with one year follow up. ( Benke, T; Bodner, T; Brandauer, E; Mueller, J; Poewe, W; Seppi, K; Weirich-Schwaiger, H; Wenning, GK, 2001) |
| "A wide variety of models of Huntington's disease have been developed including yeast, Caenorhabditis elegans, Drosophila melanogaster and mouse." | 2.42 | Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? ( Bates, GP; Hockly, E, 2003) |
| "The neurodegenerative disorders (Parkinson's disease, Alzheimer's dementia, Huntington's disease, cerebellar degeneration) are common medical and social problems." | 2.40 | [Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities]. ( Klivényi, P; Vécsei, L, 1997) |
| "Patient 2 showed persecution paranoia and motor impersistence at the age of 42." | 1.34 | Monozygotic twins suffering from Huntington's disease show different cognitive and behavioural symptoms. ( Garamendi, I; Gómez-Esteban, JC; Lezcano, E; Pérez, T; Tijero, B; Velasco, F; Zarranz, JJ, 2007) |
| "Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral sclerosis and which is currently tested in clinical trials for treatment of HD." | 1.31 | Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. ( Kosinski, CM; Landwehrmeyer, GB; Lüesse, HG; Milkereit, A; Milkereit, E; Puls, C; Schiefer, J; Sprünken, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 20 (83.33) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aziz, NA | 1 |
| van der Burg, JM | 1 |
| Landwehrmeyer, GB | 3 |
| Brundin, P | 1 |
| Stijnen, T | 1 |
| Roos, RA | 1 |
| Squitieri, F | 2 |
| Orobello, S | 1 |
| Cannella, M | 1 |
| Martino, T | 1 |
| Romanelli, P | 1 |
| Giovacchini, G | 1 |
| Frati, L | 1 |
| Mansi, L | 1 |
| Ciarmiello, A | 2 |
| Armstrong, MJ | 1 |
| Miyasaki, JM | 1 |
| Schiefer, J | 1 |
| Lüesse, HG | 1 |
| Sprünken, A | 1 |
| Puls, C | 1 |
| Milkereit, A | 1 |
| Milkereit, E | 1 |
| Kosinski, CM | 1 |
| Cepeda, C | 1 |
| Hurst, RS | 1 |
| Calvert, CR | 1 |
| Hernández-Echeagaray, E | 1 |
| Nguyen, OK | 1 |
| Jocoy, E | 1 |
| Christian, LJ | 1 |
| Ariano, MA | 1 |
| Levine, MS | 1 |
| Bates, GP | 2 |
| Hockly, E | 2 |
| Hersch, SM | 1 |
| Marti, M | 1 |
| Mela, F | 1 |
| Ulazzi, L | 1 |
| Hanau, S | 1 |
| Stocchi, S | 1 |
| Paganini, F | 1 |
| Beani, L | 1 |
| Bianchi, C | 1 |
| Morari, M | 1 |
| Qin, ZH | 1 |
| Wang, J | 1 |
| Gu, ZL | 1 |
| Tse, J | 1 |
| Barker, AL | 1 |
| Moolman, DL | 1 |
| Beunard, JL | 1 |
| Revington, AP | 1 |
| Holt, K | 1 |
| Sunshine, S | 1 |
| Moffitt, H | 1 |
| Sathasivam, K | 1 |
| Woodman, B | 1 |
| Wanker, EE | 1 |
| Lowden, PA | 1 |
| Haaxma, CA | 1 |
| Kremer, HP | 1 |
| van de Warrenburg, BP | 1 |
| Wu, J | 1 |
| Tang, T | 1 |
| Bezprozvanny, I | 1 |
| Gómez-Esteban, JC | 1 |
| Lezcano, E | 1 |
| Zarranz, JJ | 1 |
| Velasco, F | 1 |
| Garamendi, I | 1 |
| Pérez, T | 1 |
| Tijero, B | 1 |
| Bonelli, RM | 3 |
| Hofmann, P | 1 |
| Dubois, B | 1 |
| de Yébenes, JG | 1 |
| Kremer, B | 1 |
| Gaus, W | 1 |
| Kraus, PH | 1 |
| Przuntek, H | 1 |
| Dib, M | 1 |
| Doble, A | 1 |
| Fischer, W | 1 |
| Ludolph, AC | 1 |
| Ciammola, A | 1 |
| Colonnese, C | 1 |
| Klivényi, P | 1 |
| Vécsei, L | 1 |
| Centonze, D | 1 |
| Calabresi, P | 1 |
| Pisani, A | 1 |
| Marinelli, S | 1 |
| Marfia, GA | 1 |
| Bernardi, G | 1 |
| Rosas, HD | 1 |
| Koroshetz, WJ | 1 |
| Jenkins, BG | 1 |
| Chen, YI | 1 |
| Hayden, DL | 1 |
| Beal, MF | 1 |
| Cudkowicz, ME | 1 |
| Bodner, T | 2 |
| Jenner, C | 1 |
| Benke, T | 2 |
| Ober, A | 1 |
| Seppi, K | 2 |
| Fleischhacker, WW | 1 |
| Mueller, J | 1 |
| Brandauer, E | 1 |
| Weirich-Schwaiger, H | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Niederwieser, G | 2 |
| Diez, J | 1 |
| Költringer, P | 1 |
5 reviews available for riluzole and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Topics: Acetamides; Animals; Antioxidants; Creatine; Disease Models, Animal; Evaluation Studies as Topic; Hu | 2003 |
Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
Topics: Amantadine; Anti-Dyskinesia Agents; Antiparkinson Agents; Eicosapentaenoic Acid; Fatty Acids, Unsatu | 2003 |
Development of novel therapies for Huntington's disease: hope and challenge.
Topics: Amantadine; Animals; Cell Transplantation; Drugs, Chinese Herbal; Humans; Huntingtin Protein; Huntin | 2005 |
A systematic review of the treatment studies in Huntington's disease since 1990.
Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Ag | 2007 |
[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities].
Topics: Aged; Aging; Alzheimer Disease; Calcium Channel Blockers; Cerebellar Diseases; Dementia; Electron Tr | 1997 |
6 trials available for riluzole and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Weight loss in Huntington disease increases with higher CAG repeat number.
Topics: Adult; Aged; Animals; Body Mass Index; Body Weight; Disease Models, Animal; Energy Intake; Female; H | 2008 |
Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.
Topics: Adult; Aged; Biomarkers; Brain; Fluorodeoxyglucose F18; Glucose; Humans; Huntington Disease; Linear | 2009 |
Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.
Topics: Chorea; Dose-Response Relationship, Drug; Double-Blind Method; Excitatory Amino Acid Antagonists; Fe | 2003 |
Riluzole in Huntington's disease: a 3-year, randomized controlled study.
Topics: Adult; Aged; Behavior; Cognition; Depression; Female; Humans; Huntington Disease; Male; Middle Aged; | 2007 |
Riluzole therapy in Huntington's disease (HD).
Topics: Adult; Basal Ganglia; Chorea; Excitatory Amino Acid Antagonists; Female; Humans; Huntington Disease; | 1999 |
Riluzole in Huntington's disease (HD): an open label study with one year follow up.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hu | 2001 |
13 other studies available for riluzole and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
Topics: Adult; Amantadine; Anticonvulsants; Chorea; Evidence-Based Medicine; Humans; Huntington Disease; Ril | 2012 |
Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Topics: Animals; Cell Nucleus; Cerebral Cortex; Corpus Striatum; Excitatory Amino Acid Antagonists; Exons; G | 2002 |
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Disease Progression; Electrophysi | 2003 |
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease.
Topics: Acetylcholine; Animals; Convulsants; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; g | 2003 |
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.
Topics: Animals; Benzothiazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Genotype; | 2006 |
Delayed amnesic syndrome after riluzole autointoxication in Huntington disease.
Topics: Adult; Amnesia; Drug Overdose; Female; Humans; Huntington Disease; Neuroprotective Agents; Poisoning | 2006 |
Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.
Topics: Amines; Animals; Apoptosis; Cells, Cultured; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Anta | 2006 |
Monozygotic twins suffering from Huntington's disease show different cognitive and behavioural symptoms.
Topics: Adult; Anxiety; Behavioral Symptoms; Brain; Chorea; Cognition Disorders; Humans; Huntington Disease; | 2007 |
Neuroprotective effects of riluzole in Huntington's disease.
Topics: Aged; Aged, 80 and over; Brain; Controlled Clinical Trials as Topic; Female; Follow-Up Studies; Huma | 2008 |
Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glutamic Acid; | 1998 |
Intoxication with riluzole in Huntington's disease.
Topics: Adult; Dose-Response Relationship, Drug; Drug Overdose; Female; Humans; Huntington Disease; Neuropsy | 2001 |
Riluzole and olanzapine in Huntington's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Huntington Disease; Male; Neuroprotect | 2002 |
Apraxia of eyelid closure in Huntington's disease.
Topics: Apraxias; Benzodiazepines; Drug Therapy, Combination; Eyelid Diseases; Female; Humans; Huntington Di | 2002 |